To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min One of the Bay Area's most ...
The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...
State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...
George is a professor of genetics at Harvard Medical School and professor of health sciences and technology at Harvard and MIT. He is a prolific researcher studying genetic sequencing, genome editing, ...
Pharmaceutical Technology on MSN
Kailera makes history with record-breaking $625m IPO
The biotech will primarily focus on taking the oral and injectable form of its lead candidate, ribupatide, through late-stage obesity trials.
When a microcap biotech transitions from obscurity to the Nasdaq Capital Market, fireworks are common. The move often signals a pivotal moment in the company’s growth trajectory, opening the door to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results